Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Gustavo Akkerman represents U.S. and international clients in a broad range of domestic and cross-border corporate transactions, including in the life sciences and financial services industries. He also advises clients on international anti-corruption matters. A licensed attorney in Brazil and a native Portuguese speaker, Mr. Akkerman helps clients navigate the Latin American business and legal environments.

  • UCB in its $2.5 billion acquisition of Ra Pharmaceuticals (Nasdaq: RARX), a biopharmaceutical company developing therapeutics for the treatment of serious diseases.
  • TRC Companies (NYSE: TRR), an engineering, environmental consulting and construction management firm, in its $595 million acquisition by New Mountain Capital.
  • Astellas Pharma in its $384 million acquisition of Ocata Therapeutics (Nasdaq: OCAT), a biotechnology company specializing in the development of stem cell-based treatments in regenerative medicine.
  • ITOCHU Corporation and ITOCHU International in the sale of PrimeSource Building Products, a North American distributor of building materials, to Platinum Equity. 
  • Allergan, in the $500 million sale of its Anda distribution business to Teva Pharmaceutical Industries.   
  • Reliance Industries Limited in the combination of its JioMusic digital music service with Saavn, a global music streaming platform.
  • Oxford Immunotec in the$170 million sale of its U.S. laboratory services business to QuestDiagnostics.
  • Stryker Corporation in its $716 million acquisition of NOVADAQ Technologies (Nasdaq: NVDQ; TSX: NDQ), a provider of fluorescence imaging solutions for minimally invasive and open surgeries.
  • Merck on the multi-year post-merger integration of Schering-Plough Corporation in certain Latin American countries, and on the post-merger integration of Cubist Pharmaceuticals and Idenix Pharmaceuticals.
  • GlaxoSmithKline in its acquisition of ex-U.S. rights relating to the Quell wearable pain relief technology from with NeuroMetrix, Inc.
  • A Medium Corporation (medium.com) in its acquisition of Embed.ly.
  • Assurant in its acquisition of Mobile Defense, a technology company focused on mobile device diagnostics and data processingfor user assistance and predictive forecasting.
  • OrbiMed Advisors in secured debt and equity investments in biotechnology, pharmaceutical and medical device companies.
  • Several U.S. based and foreign private equity funds managed by a significant private equity management group and with assets of more than $1.3 billion in aggregate, in connection with subscription credit facilities secured by their uncalled capital commitments. 
  • Tricadia Capital Management as an anchor equity investor in the recapitalization of Bridgeview Bancorp, Inc., a regional bank holding company based in the Chicago metropolitan area.
  • Advised Acorda Therapeutics, Inc., in its public offering of $345 million of 1.75% Convertible Senior Notes due 2021 and in a $75 million private placement of shares of common stock.
  • Represented the underwriters in the U.S. initial public offering of ordinary shares of uniQure N.V., an Amsterdam-based gene therapy company.
  • Represented the underwriters in the initial public offering of Retrophin, Inc., a biopharmaceutical company focused on treatment of catastrophic diseases.
  • Represented the underwriters in the initial public offering of Bankwell Financial Group, Inc., the bank holding company for Bankwell, a community bank based in New Canaan, Connecticut.
  • Represented a Fortune 50 company and a Fortune Global 500 company in whistleblower Foreign Corrupt Practices Act investigations.
  • Advised a Fortune 100 company and a Fortune Global 500 company in anti-corruption compliance risk assessments.